Startup And Fundraising 10 September 2026
CDSCO Pushes Risk‑Based Rules to Boost Indian Pharma Exports
The Central Drugs Standard Control Organization (CDSCO) announced a shift to smarter, risk‑based regulation aimed at simplifying compliance for Indian pharmaceutical companies. The change backs the iPHEX 2026 plan, targeting roughly $1.4 billion in export opportunities and easing the path for manufacturers to reach global markets.
CDSCO adopts risk‑based regulation
- New framework focuses on scientific risk assessment rather than blanket checks, speeding up approval timelines.
- Supports the iPHEX 2026 export drive, which aims to generate about $1.4 billion for Indian pharma.
The approach is expected to cut administrative burdens, help companies scale faster, and make Indian medicines more competitive abroad. Read full article
Need help understanding this update?
Connect with our domain experts instantly via WhatsApp for customized legal guidance.